In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators

Biomaterials

Volumn 30, Issue 4, 2009, Pages 638-648

  Rossi, Nicholas A A ^a   Mustafa, Ibrahim ^a   Jackson, John K ^a   Burt, Helen M ^a   Horte, Sonja A ^a   Scott, Mark D ^a   Kizhakkedathu, Jayachandran N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blood compatibility; Desferrioxamine; Iron chelation therapy; Macromolecular therapeutics; Poly(ethylene glycol) (PEG); RAFT polymerization

Indexed keywords

ABS RESINS; AGGLOMERATION; BINDING ENERGY; BLOOD; BLOOD SUBSTITUTES; CELLS; CHROMATOGRAPHIC ANALYSIS; COLLOIDS; COPOLYMERIZATION; ENDOTHELIAL CELLS; ESTERS; ETHYLENE; ETHYLENE GLYCOL; FUNCTIONAL POLYMERS; GELATION; GLYCOLS; HOLOGRAMS; IRON COMPOUNDS; LIVING POLYMERIZATION; MACROMOLECULES; MOLECULAR WEIGHT; MONOMERS; NUCLEAR MAGNETIC RESONANCE; ORGANIC COMPOUNDS; PLASTIC PRODUCTS; PLATELETS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS;

BLOOD COMPATIBILITY; DESFERRIOXAMINE; IRON CHELATION THERAPY; MACROMOLECULAR THERAPEUTICS; POLY(ETHYLENE GLYCOL) (PEG); RAFT POLYMERIZATION;

CHELATION;

CHELATING AGENT; DEFEROXAMINE; MACROGOL;

ARTICLE; BIODEGRADABILITY; BLOOD COMPATIBILITY; CELL VIABILITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ERYTHROCYTE AGGREGATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IRON BINDING CAPACITY; IRON CHELATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL THROMBOPLASTIN TIME; POLYMERIZATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY;

BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION; CATALYSIS; CELL DEATH; CELL SURVIVAL; COMPLEMENT ACTIVATION; DEFEROXAMINE; ERYTHROCYTE AGGREGATION; ERYTHROCYTES; HEMOGLOBINS; HEMOLYSIS; HUMANS; IRON; IRON CHELATING AGENTS; MOLECULAR WEIGHT; OXIDATION-REDUCTION; PLATELET ACTIVATION; PLATELET-RICH PLASMA; POLYETHYLENE GLYCOLS; SPECTROPHOTOMETRY, ULTRAVIOLET; THROMBELASTOGRAPHY;

EID: 56449096123     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.09.057     Document Type: Article

References (62)

1. Hentze M.W., and Muckenthaler M.U. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 (2004) 285-295
2. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst 35 (1998) 585-631
3. Hershko C., Graham G., Bates G.W., and Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40 (1978) 255-263
4. Batts K.P. Iron overload syndromes and the liver. Modern Pathol 20 (2007) S31-S39
5. Scott M.D., and Eaton J.W. Markers of free radical-mediated tissue injury. In: Wallace K.B. (Ed). Free radical toxicology (1997), Taylor & Francis, Washington, D.C. 401-420
6. Hebbel R.P. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 14 (1985) 129-140
7. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
8. Wong C., and Richardson D.R. β-Thalassemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 35 (2003) 1144-1149
9. Kalinowski D.S., and Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57 (2005) 547-583
10. Bernhardt P.V. Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalton Trans 30 (2007) 3214-3220
11. Richardson D.R. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 75 (1997) 1164-1180
12. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42 (2002) 267-281
13. Buss J.L., Torti F.M., and Torti S.V. The role of iron chelation in cancer therapy. Curr Med Chem 10 (2003) 1021-1034
14. Whitnall M., Howard J., Ponka P., and Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103 (2006) 14901-14906
15. Hallaway P.E., Eaton J.W., Panter S.S., and Hedlund B.E. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci U S A 86 (1989) 10108-10112
16. Aouad F., Florence A., Zhang Y., Collins F., Henry C., Ward R.J., et al. Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339 (2002) 470-480
17. Franchini M., Gandini G., de Gironcoli M., Vassanelli A., Borgna-Pignatti C., and Aprili G. Safety and efficacy of subcutaneous bolus injection deferoxamine in adult patients with iron overload. Blood 95 (2000) 2776-2779
18. Liu Z.D., and Hider R.C. Design of iron chelators with therapeutic application. Coor Chem Rev 232 (2002) 151-171
19. Zhou T., Neubert H., Liu D.Y., Liu Z.D., Ma Y.M., Kong X.L., et al. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis. J Med Chem 49 (2006) 4171-4182
20. Polomoscanik S.C., Cannon C.P., Neenan T.X., Holmes-Farley S.R., Mandeville W.H., and Dhal P.K. Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation. Biomacromolecules 6 (2005) 2946-2953
21. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2 (2003) 214-221
22. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Drug Discov 2 (2003) 347-360
23. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Int Ed. Angew Chem 45 (2006) 1198-1215
24. Dhal P.K., Huval C.C., and Holmes-Farley S.R. Polymeric sequestrants as nonabsorbed human therapeutics. Drug Discovery Dev 1 (2006) 383-404
25. Dhal P.K., Holmes-Farley S.R., Huval C.C., and Jozefiak T.H. Polymers as drugs. Adv Polym Sci 192 (2006) 9-58
26. Kiick K.L. Polymer therapeutics. Science 317 (2007) 1182-1183
27. Dragsten P.R., Hallaway P.E., Hanson G.J., Berger A.E., Bernard B., and Hedlund B.E. First human studies with a high-molecular-weight iron chelator. J Lab Clin Med 135 (2000) 57-65
28. Harmatz P., Grady R.W., Dragsten P., Vichinsky E., Giardina P., Madden J., et al. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br J Haematol 138 (2007) 374-381
29. Chiefari J., Chong Y.K., Ercole F., Krstina J., Jeffery J., Le T.P.T., et al. Living free-radical polymerization by reversible addition-fragmentation chain transfer: the RAFT process. Macromolecules 31 (1998) 5559-5562
30. Quinn J.F., Rizzardo E., and Davis T.P. Ambient temperature reversible addition-fragmentation chain transfer polymerization. Chem Commun (2001) 1044-1045
31. Goto A., Sato K., Tsujii Y., Fukuda T., Moad G., Rizzardo E., et al. Mechanism and kinetics of RAFT-based living radical polymerizations of styrene and methyl methacrylate. Macromolecules 34 (2001) 402-408
32. Vana P., Quinn J.F., Davis T.P., and Barner-Kowollik C. Recent advances in the kinetics of reversible addition fragmentation chain-transfer polymerization. Aust J Chem 55 (2002) 425-431
33. Moad G., Rizzardo E., and Thang S.H. Living radical polymerization by the RAFT process. Aust J Chem 58 (2005) 379-410
34. Matyjaszewski K., and Xia J. Atom transfer radical polymerization. Chem Rev 101 (2001) 2921-2990
35. Rossi N.A.A., Zou Y., Scott M.D., and Kizhakkedathu J.N. RAFT synthesis of acrylic copolymers containing poly(ethylene glycol) and dioxolane functional groups: towards well-defined aldehyde containing copolymers for bio-conjugation. Macromolecules 41 (2008) 5272-5282
36. Kainthan R.K., Gnanamani M., Ganguli M., Ghosh T., Brooks D.E., Maiti S., et al. Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. Biomaterials 27 (2006) 5377-5390
37. Kainthan R.K., Hester S.R., Levin E., Devine D.V., and Brooks D.E. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials 28 (2007) 4581-4590
38. Kizhakkedathu J.N., and Brooks D.E. Synthesis of poly(N,N-dimethylacrylamide) brushes from charged polymeric surfaces by aqueous ATRP: effect of surface initiator concentration. Macromolecules 36 (2003) 591-598
39. Winterbourn C.C. Free-radical production and oxidative reactions of hemoglobin. Environ Health Perspect 64 (1985) 321-330
40. Salooja N., and Perry D.J. Thromboelastography. Blood Coagul Fibrinolysis 12 (2001) 327-337
41. Haemoscope user manual (1999-2007), Haemoscope Corporation, IL
42. Beillatt J., and Dorson W.J. Hemocompatibility studies: quantification of serum complement activation by polymeric membranes and materials. ASAIO J 7 (1984) 57-63
43. Yu J., Lamba N.M., Courtney J.M., Whateley T.L., Gaylor T.D., Lowe G.D., et al. Polymeric biomaterials: influence of phosphorylcholine polar groups on protein adsorption and complement activation. Int J Artif Organs 17 (1994) 499-504
44. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Drug Deliv Rev 55 (2003) 1261-1277
45. Halliwell B., and Gutteridge J.M.C. Free radicals in biology and medicine (1989), Claredon Press, Oxford
46. Bergeron R.J., Wiegand J., McManis J.S., Bussenius J., Smith R.E., and Weimar W.R. Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency. J Med Chem 46 (2003) 1470-1477
47. Barnham K.J., Masters C.L., and Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3 (2004) 205-214
48. Scott M.D., van Der Berg J.J.M., and Repka T. Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest 91 (1993) 1706-1712
49. Scott M.D., and Eaton J.W. Thalassaemic erythrocytes: cellular suicide arising from iron and glutathione-dependent oxidation reactions?. Br J Haematol 91 (1995) 811-819
50. Scott M.D., Yang L., Ulrich P., and Shupe T. Pharmacologic interception of heme: a potential therapeutic strategy for the treatment of beta thalassemia?. Redox Rep 3 (1997) 159-167
51. 2 injury in β thalassemic erythrocytes: protective role of catalase and the prooxidant effects of GSH. Free Radic Biol Med 40 (2006) 1264-1272
52. Scott M.D. Intraerythrocytic iron chelation: a new therapy for thalassemia?. Hematology 6 (2001) 73-89
53. Poot M., Rabinovitch P.S., and Hoehn H. Free radical mediated cytotoxicity of desferrioxamine. Free Radic Res Commun 6 (1989) 323-328
54. Gorbet M.B., and Sefton M.V. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25 (2004) 5681-5703
55. Lamba N.M.K., Courtney J.M., Gaylor J.D., and Lowe G.D.O. In vitro investigation of the blood response to medial grade PVC and the effect of heparin on the blood response. Biomaterials 21 (2000) 89-96
56. Aravind S., Paul W., Vasudev S.C., and Sharma C.P. Polyethylene glycol (PEG) modified bovine pericardium as a biomaterial: a comparative study on immunogenicity. J Biomater Appl 13 (1998) 158-165
57. Jantova J. Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers. ASAIO J 46 (2000) S53-S62
58. Payne M.S., and Horbett T.A. Complement activation by hydroxyethylmethacrylate-ethylmethacrylate copolymers. J Biomed Mater Res 21 (1987) 843-859
59. Chien S. Biophysical behavior of red cells in suspensions. In: Surgenor D.M. (Ed). Red blood cell (1975), Academic Press, New York 1032-1121
60. Armstrong J.K., Wenby R.B., Meiselman H.J., and Fisher T.C. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys J 87 (2004) 4259-4270
61. Menu P., Bleeker W., Longrois D., Caron A., Faivre-Fiorina B., Muller S., et al. In vivo effects of Hb solutions on blood viscosity and rheologic behavior of RBCs: comparison with clinically used volume expanders. Transfusion 40 (1999) 1095-1103
62. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. Biomed Mater Res (Appl Biomater) 48 (1999) 342-353